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Summary. Although the current guidelines for the clinical diagnosis of multi-
ple system atrophy (MSA) do not require structural or functional brain imaging,
investigations utilizing positron emission tomography (PET) have been helpful
diagnostically in differentiating between MSA and primary autonomic failure;
idiopathic Parkinson’s disease; and sporadic olivopontocerebellar atrophy.
These investigations have demonstrated different patterns of cerebral glucose
utilization and of nigrostriatal projection abnormalities among these disorders
and between the cerebellar and parkinsonian forms of MSA. Most of the studies
have focused upon patients with well-established disease and none have exam-
ined the utility of PET imaging in early stage patients with follow-up of clinical
course and autopsy verification to ensure accuracy of diagnosis and to deter-
mine the sensitivity and specificity of PET techniques for diagnosis. Recent
PET studies have revealed denervation of myocardial post-ganglionic sympa-
thetic neurons in some MSA patients, indicating that this disorder can affect the
peripheral autonomic as well as the central nervous system. Investigations uti-
lizing ligands to quantify central nervous system dopaminergic and cholinergic
terminals have begun to provide insight into the neurochemical disorders that
may underlie two of the sleep disturbances common in MSA, rapid eye move-
ment sleep behavior disorder and obstructive sleep apnea.
Keywords: Positron emission tomography, functional imaging, multiple system
atrophy.
Introduction
A consensus conference established the current diagnostic criteria for possible,
probable, and definite multiple system atrophy (MSA) (Gilman et al., 1999b).
The criteria are purely clinical, requiring neither structural nor functional ima-
ging for diagnosis; nevertheless, imaging has proved useful as a research tool
in this disorder. Positron emission tomography (PET) has contributed to clin-
ical diagnosis by differentiating MSA from other related disorders, including
pure autonomic failure (PAF), idiopathic Parkinson’s disease (IPD), progressive
supranuclear palsy (PSP) and sporadic olivopontocerebellar atrophy (sOPCA).
Most of these investigations have involved subjects with well-characterized
disease and not subjects in the earliest stages of the disease. Hence there are
no published studies that have systematically examined the utility of PET ima-
ging in early stage patients with determination of the subsequent clinical course
and autopsy verification to ensure accuracy of diagnosis. Studies such as this
would help evaluate the sensitivity and specificity of PET techniques for diag-
nosis. PET also has been used to characterize subgroups of MSA, detect invol-
vement of other organ systems, and examine the pathogenesis of the sleep
disturbances commonly found in this disease, rapid eye movement (REM) sleep
behavior disorder (RBD) and obstructive sleep apnea (OSA). This review of
functional imaging studies with PET in MSA briefly summarizes the results
presented in representative research papers in these areas; this is not intended
to be an exhaustive review of all PET imaging studies in MSA. Although
this paper specifically concerns PET, other scanning techniques are mentioned
briefly when necessary for clarity and accuracy in discussing the results of indi-
vidual investigations. The other scanning techniques include computed tomo-
graphy (CT), magnetic resonance imaging (MRI) and single photon emission
computed tomography (SPECT). Table 1 provides a brief summary of the radio-
tracer ligands used in PET investigations of MSA discussed in this paper.
Results and discussion
Differential diagnosis of MSA and PAF
Fulham et al. (1991) used computed tomography (CT), magnetic resonance
imaging (MRI) and PET with [18F]fluorodeoxyglucose (FDG-PET) to character-
ize the neuroimaging features of MSA and PAF. They also examined the utility
of these techniques in distinguishing between these disorders. They investigated
30 patients with MSA and 15 with PAF. The MSA group included eight patients
Table 1. Radiotracer ligands used in PET investigations of MSA described in this review, their anatomical
localizations, and the functions they can be used to measure
Radiotracer ligand Localization Function measured
[18F]fluorodeoxyglucose Cerebral cortex, cerebellum,
thalamus, basal ganglia








Type 2 vesicular monoamine
transporter density
[11C]diprenorphine Striatum, thalamus, amygdala,
cingulate gyrus, insular cortex,
frontal cortex
Nonselective opoid receptor
sites (including m, k, and d)








with MSA of the cerebellar type (MSA-C), seven patients with MSA of the
parkinsonian type (MSA-P) and 15 patients who had both cerebellar and par-
kinsonian features. In the MSA but not the PAF patients they found cerebellar
atrophy on CT and MRI, signal hypointensity in the posterolateral putamen on
MRI, and a generalized reduction in local cerebral metabolic rates for glucose
(lCMRglc) with FDG-PET. Glucose hypometabolism was most prominent in
the cerebellum, brainstem, striatum, and frontal and motor regions of the cere-
bral cortex. They concluded that neuroimaging studies clearly distinguish MSA
from PAF.
Distinguishing between MSA, PD and PSP
Burn et al. (1994) utilized [18F]fluorodopa with PET (FD-PET), a means of
quantifying the density of presynaptic dopaminergic terminals, to examine the
pattern of nigrostriatal dopaminergic dysfunction in patients with parkinsonian
syndromes. The group included 27 normal control subjects, 28 patients with
IPD, 25 with MSA, and 10 with PSP (termed Steele-Richardson-Olszewski
syndrome in this paper). The authors used a discriminant function analysis in
assessing the ability of FD-PET to categorize individual parkinsonian patients
based upon tracer uptake in the caudate nucleus and putamen. The discriminant
function analysis assigned all control subjects to a normal category. One patient
with a parkinsonian syndrome out of the 63 studied was classified as normal
on the basis of PET findings, although this patient’s scan showed significantly
reduced uptake in the putamen. Discriminant function analysis was less effec-
tive than clinical criteria at distinguishing different categories of parkinsonian
syndrome. Patients labeled clinically as having typical or atypical parkinsonian
syndromes were assigned the same category on PET criteria 64% and 69% of
the time, respectively. When the three categories of IPD, MSA, and PSP were
considered together, clinical and FD-PET findings correlated in 64% of patients
assigned a diagnosis of IPD and 70% of those given a diagnosis of PSP. MSA
was less readily discriminated; these patients were assigned to MSA, IPD, and
PSP groups with equal frequency. Hence even in well-established patients,
FD-PET did not differentiate sharply between these three disorders, at least in
comparison with clinical categorization.
Otsuka et al. (1997) reported PET examinations of striatal FD-PET uptake
and FDG-PET in nine patients with MSA and 15 with IPD as compared with
equivalent numbers of normal controls. Five of the MSA patients had OPCA,
two had striatonigral degeneration and two had MSA-P (described as Shy-Drager
syndrome). FD uptake ratios to the occipital cortex in MSA at 120 min after
administration were 2.07 0.31 (mean SD) in the caudate nucleus (CN) and
1.96 0.29 in the putamen (PUT), which were decreased compared to con-
trols (2.72 0.11 CN, 2.71 0.10 PUT). In the IPD patients the values were
2.07 0.36 CN and 1.74 0.24 PUT, which was also decreased, but the de-
crease in the putamen was greater in IPD than MSA. A caudate-putamen index
(CPI) was developed based upon differences in the uptakes in the CN and PUT
divided by the CN. The CPI was 5.6 4.6 in the MSA patients and 14.8 5.4
in the IPD patients. LCMRglc in IPD showed no difference from the normal
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controls. In MSA, lCMRglc was decreased in the frontal and the temporal
cortical regions and in the CN, PUT, cerebellum and brainstem as compared
to controls. There was considerable overlap in lCMRglc between MSA and
normal control groups, however. The authors concluded that FD-PET is useful
for distinguishing MSA from IPD, and appears more useful than FDG-PET.
Comparisons of OPCA and MSA-C
Gilman et al. (1994) used FDG-PET to examine lCMRglc in patients with MSA,
sOPCA, and dominantly inherited olivopontocerebellar atrophy (dOPCA) in
comparison with normal control subjects. In MSA, lCMRglc was significantly
decreased in the brainstem, cerebellum, putamen, thalamus, and cerebral cortex
as compared to the normal controls. In sOPCA, lCMRglc was significantly
decreased in the brainstem, cerebellum, putamen, thalamus, and cerebral cortex.
In dOPCA, lCMRglc was significantly decreased in the brainstem and cerebel-
lum but not in the other structures. Examination of lCMRglc normalized to the
cerebral cortex in comparison with normal controls revealed in MSA significant
decreases in the brainstem, cerebellum, and putamen, but in both sOPCA and
dOPCA, significant decreases were found only in the brainstem and cerebellum.
The authors concluded that these three disorders all show a marked decrease of
lCMRglc in the brainstem and cerebellum but differ in the degree of hypome-
tabolism in forebrain and cerebral cortex. The results were consistent with the
possibility that, in many cases, sOPCA will evolve into MSA.
In a later investigation, Gilman et al. (1996) used ()-[11C]dihydrotetrabena-
zine, a newly developed ligand for the type 2 vesicular monoamine transporter
(VMAT2), with PET (DTBZ-PET) to examine striatal monoaminergic presynap-
tic terminals in four MSA and eight sOPCA patients compared with nine normal
control subjects. Specific binding in the striatum was significantly reduced in
MSA as compared with the normal controls, with average reductions of 61%
in the CN (p¼ 0.002) and 58% in the PUT (p¼ 0.009). Smaller reductions were
found in the sOPCA group, averaging 26% in the CN (p¼ 0.05) and 24% in the
PUT (p¼ 0.11). Mean blood-to-brain DTBZ transport (K1) was significantly dif-
ferent between groups only in the cerebellum, with values for the sOPCA group
diminished compared with the normal control group. Cerebellar K1 was not sig-
nificantly decreased in the MSA group. The finding of reduced striatal VMAT2 in
sOPCA suggested nigrostriatal pathology, indicating that some may later develop
symptomatic extrapyramidal disease and consequently progress to MSA.
Subsequently, Gilman et al. (1999a) examined the density of striatal pre-
synaptic monoaminergic terminals using the (þ) enantiomer for the VMAT2,
(þ)-[11C]DTBZ, with PET in eight MSA-P, eight MSA-C, six sOPCA patients
and seven normal controls. As compared with controls, binding was signifi-
cantly reduced in the PUT of all patient groups, and binding values were sig-
nificantly lower in MSA-P than in MSA-C, and significantly lower in MSA-C
than in sOPCA. Mean K1 was significantly decreased in the PUT of all patient
groups and in the cerebellar hemispheres of MSA-C and sOPCA but not
MSA-P groups, compared with controls. Significant negative correlations were
found between striatal binding and the severity of parkinsonian features and
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between cerebellar K1 and the severity of cerebellar dysfunction. The results
indicated differences between MSA-P and MSA-C groups reflecting differential
severity in degeneration of nigrostriatal and cerebellar systems. The findings
also showed that some sOPCA patients have subclinical nigrostriatal dysfunc-
tion and are at risk of developing MSA with disease progression.
Rinne et al. (1995) examined 10 patients with sOPCA and autonomic failure
in comparison to normal control subjects using PET with [11C]diprenorphine
(a nonspecific opioid antagonist) and [18F]FD. The mean caudate-occipital uptake
ratio for [11C]diprenorphine was significantly reduced to 88% and the putamen-
occipital uptake ratio to 85% of the control values. Individually, four of the 10
patients had significantly reduced opioid binding in the PUT. Mean PUT FD-PET
uptake was significantly diminished (to 71% of the control mean); individually
seven patients had significantly reduced uptake. The authors found a significant
positive correlation between putamen-occipital uptake ratios for [11C]diprenor-
phine and PUT uptake of FD. They concluded that subclinical nigrostriatal
dysfunction occurs in a majority of patients with sOPCA, in accordance with
its status as part of the spectrum of MSA. The difficulty with this conclusion is
that their patients all had autonomic failure, indicating that they already had
MSA of the cerebellar type. Hence their results did not demonstrate that
sOPCA is necessarily part of the spectrum of MSA.
Cardiac imaging of PD and MSA
Metaiodobenzylguanidine (MIBG) is a norepinephrine analogue that is taken up
and stored in sympathetic nerve endings, and when labeled with [123I], MIBG can
be used with single photon emission computed tomography (SPECT) to examine
peripheral postganglionic sympathetic neuronal terminals. Multiple imaging
studies with [123I]MIBG in IPD patients have shown decreased cardiac uptake,
indicating myocardial postganglionic sympathetic dysfunction (Takatsu et al.,
2000; Reinhardt et al., 2000; Druschky et al., 2000; Braune et al., 1999; Orimo
et al., 1999; Satoh et al., 1999; Yoshita, 1998). Most investigations have involved
IPD patients in Hoehn and Yahr stages 3–5, but some have shown denervation
at earlier stages, including patients with and without autonomic dysfunction
(Courbon et al., 2003). At Hoehn and Yahr stage 1, however, uptake has been
reported to be normal (Satoh et al., 1999). In several MIBG investigations of
MSA, myocardial uptake was no different from normal controls (Taki et al., 2000;
Braune et al., 1999; Takatsu et al., 2000; Reinhardt et al., 2000). In a few reports,
however, MSA subjects showed reduced uptake as compared to normal controls,
although IPD patients in the same studies showed much greater levels of dener-
vation (Yoshita, 1998; Druschky et al., 2000; Hirayama et al., 1995).
Although investigations with SPECT and MIBG have provided important
information about peripheral autonomic involvement in IPD, the tracer has
several drawbacks. Single-photon scintigraphic imaging devices have inherent
shortcomings in spatial resolution and measurement of tissue radioactivity that
limit attempts to quantify radiotracer ligand uptake. Most investigations utilize
the ratio of [123I]MIBG activity in the heart divided by activity in the medias-
tinum to measure cardiac nerve density. In contrast, PET imaging offers excel-
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lent spatial resolution and accurate measurements of tissue radioactivity con-
centrations. PET imaging with the sympathetic nerve tracer [11C]meta-hydrox-
yephedrine ([11C]HED) not only permits precise quantification of cardiac
sympathetic nerve density, but also allows for detailed assessment of any
regional variation in left ventricular cardiac sympathetic innervation (Raffel
and Wieland, 2001). For these reasons, PET studies have been initiated with
[11C]hydroxyephedrine (HED), which enters myocardial sympathetic endings
primarily through specific uptake into the neuronal norepinephrine transporter.
Berding et al. (2003) reported the results of a pilot study investigating seven
patients, two with MSA and orthostatic hypotension (OH), three with probable
IPD and OH, one with probable IPD without OH, and one with possible IPD
without OH. Ratios of HED uptake in the myocardium to the liver at 5 and 40
minutes post injection were calculated. Also, tracer influx rates (K1) were com-
puted based upon kinetic modeling. Compared with MSA patients, IPD patients
with OH showed lower uptake ratios at both time points and lower K1 values.
The patient with probable IPD without OH showed intermediate values of both
uptake ratios and K1. In the patient with possible IPD, uptake ratios and K1
values did not differ from those observed in MSA. The authors concluded that
measurement of myocardial innervation may contribute to the differential diag-
nosis of parkinsonian disorders and suggested a need for quantitative pathophy-
siological imaging, particularly at early stages of disease.
Gilman et al. (2004) recently reported preliminary results of an investigation
utilizing HED for cardiac imaging of five patients with MSA, two with pro-
gressive supranuclear palsy (PSP) and 10 normal subjects using HED with PET.
The HED dose of 20 1 mCi was injected intravenously and a dynamic
sequence of scans was acquired for 40 minutes. Cardiac images were sliced
by computer algorithm into eight short-axis images, each subdivided into 60
angular sectors. Tissue concentrations of HED at 30 to 40 minutes post-injec-
tion were normalized by dividing by the integral of the blood time-activity
curve, providing a retention index (RI) for each myocardial region, reflecting
the ability of the sympathetic neurons to take up and store norepinephrine. Two
MSA patients had RI values over 2.5 standard deviations below normal levels
for all 480 sectors. One of these expired months after the study, and brain
autopsy verified the diagnosis. In the third MSA patient, 20% of the sectors
showed RI values over 2.5 SD below normal levels. The two remaining MSA
patients and both PSP patients had RI values within normal levels throughout.
The findings show that some MSA patients have severe post-ganglionic sym-
pathetic denervation of the heart whereas PSP patients have normal innervation.
This indicates that peripheral sympathetic neurons can be affected in MSA.
Pathophysiology of sleep disorders in MSA
MSA is associated with multiple sleep disorders, among them REM sleep
behavior disorder (RBD) and obstructive sleep apnea (OSA). In two recent
exploratory investigations, Gilman et al. (2003a, b) examined the neuro-
chemical basis of these disturbances. Thirteen MSA patients were studied
and compared with normal control subjects. The first study (Gilman et al.,
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2003a) examined the neurochemical abnormalities that may underlie RBD.
Nocturnal, laboratory-based polysomnography (PSG) was used to rate the
severity of REM atonia loss by the percentage of REM sleep with tonically
increased electromyographic (EMG) activity and the percentage of REM sleep
with phasic EMG bursts. PET with (þ)-[11C]DTBZ was used to determine
the density of striatal presynaptic monoaminergic terminals, and SPECT with
()-5-[123I]iodobenzovesamicol ([123I]IBVM) to measure the density of thala-
mic presynaptic cholinergic terminals. The MSA subjects showed decreased
mean DTBZ binding in the striatum (p<0.0001) compared with 15 normal
control subjects and decreased IBVM binding in the thalamus (p<0.001) com-
pared with 12 normal control subjects. Moreover, in the MSA group, striatal
DTBZ binding was inversely correlated with the severity of REM atonia loss
(p¼ 0.003). Thalamic IBVM binding, however, was not correlated to the sever-
ity of REM atonia loss. The study suggested that decreased nigrostriatal dopa-
minergic projections may contribute to RBD in MSA.
The second study (Gilman et al., 2003b) explored the neurochemical basis
of OSA utilizing the same patients, normal control subjects, and PET=SPECT
ligands. The investigators used the same nocturnal, laboratory-based PSG, but
in this study they computed the apnea-hypopnea index during sleep to rate the
severity of OSA. In the MSA group, thalamic IBVM binding was inversely
correlated with the severity of OSA (p¼ 0.011). Striatal DTBZ binding was
not correlated with the severity of OSA (p¼ 0.19). These findings suggested
that decreased pontine cholinergic projections may contribute to OSA in MSA.
These studies were designed with the hypothesis that denervation of both
dopaminergic nigrostriatal terminals and pontine cholinergic nuclei would show
a relationship to RBD severity. Multiple investigations in experimental animals
indicate the important function of these nuclei in REM sleep and are likely to
be important in RBD (Rye, 1997). At the time of publication of the studies cited
above, we had no means of imaging these brainstem nuclei, as IBVM with
SPECT provided inadequate resolution to analyze brainstem cholinergic content.
In a current ongoing investigation, however, we have utilized the cholinergic
marker N-[11C]Methylpiperidin-4-yl Propionate ([11C]PMP), and preliminary
data suggest participation of these cholinergic neurons in RBD of MSA
patients. These findings have not as yet been published.
Future studies of MSA with PET
The studies reviewed above have shown that PET provides valuable informa-
tion about cerebral neurochemical changes in patients with MSA. Information
from these studies can be used to understand the pathophysiological basis of
some of the neurological disorders encountered clinically and perhaps can be
useful in differential diagnosis of the various parkinsonian syndromes. PET
scanning is a specialized technique that requires expensive equipment and
highly trained personnel but can produce multiple types of tracers designed
for specific targets. Although more limited in tracer availability and resolution,
SPECT scanning requires fewer specialized personnel and is less expensive and
more widely accessible. Future innovative studies of MSA are likely to come
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from PET centers utilizing unique specialized tracers, but important, useful
information will come from SPECT studies as well. Some of the future studies
perhaps will utilize functional imaging in the early stages of the common par-
kinsonian syndromes to determine the sensitivity and specificity of imaging in
predicting the outcome of these disorders with verification by both clinical
course and autopsy study.
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